These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32653473)

  • 1. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption.
    Dinan MA; Wilson LE; Reed SD; Griggs JJ; Norton EC
    Clin Breast Cancer; 2020 Dec; 20(6):487-494.e1. PubMed ID: 32653473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
    Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
    JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
    Gage MM; Mylander WC; Rosman M; Fujii T; Le Du F; Raghavendra A; Sinha AK; Espinosa Fernandez JR; James A; Ueno NT; Tafra L; Jackson RS
    Ann Oncol; 2018 May; 29(5):1280-1285. PubMed ID: 29788166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
    Dinan MA; Wilson LE; Reed SD
    J Natl Compr Canc Netw; 2019 Mar; 17(3):245-254. PubMed ID: 30865923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011.
    Su KW; Hall J; Soulos PR; Abu-Khalaf MM; Evans SB; Mougalian SS; Rutter CE; Davidoff AJ; Gross CP
    J Geriatr Oncol; 2016 Jan; 7(1):15-23. PubMed ID: 26704661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
    Wilson LE; Pollack CE; Greiner MA; Dinan MA
    Breast Cancer Res Treat; 2018 Jul; 170(2):361-371. PubMed ID: 29536319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
    Liu KH; Zhang L; Chen JX; Lian CL; Wang J; He ZY; Wu SG
    Breast; 2020 Feb; 49():233-241. PubMed ID: 31918322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations.
    Panattoni L; Lieu TA; Jayasekera J; O'Neill S; Mandelblatt JS; Etzioni R; Phelps CE; Ramsey SD
    Breast Cancer Res Treat; 2019 Jan; 173(2):417-427. PubMed ID: 30306429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
    Epstein AJ; Wong YN; Mitra N; Vachani A; Hin S; Yang L; Smith-McLallen A; Armstrong K; Groeneveld PW
    J Clin Oncol; 2015 Dec; 33(36):4259-67. PubMed ID: 26598749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
    Carlson JJ; Roth JA
    Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
    Hull LE; Lynch JA; Berse BB; DuVall SL; Chun DS; Venne VL; Efimova OV; Icardi MS; Kelley MJ
    Clin Breast Cancer; 2018 Apr; 18(2):135-143. PubMed ID: 29306660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.
    Zhou P; Zhang WW; Bao Y; Wang J; Lian CL; He ZY; Wu SG
    Breast; 2020 Dec; 54():319-327. PubMed ID: 33278648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
    Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
    BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
    Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
    Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
    Zipkin R; Schaefer A; Chamberlin M; Onega T; O'Malley AJ; Moen EL
    Cancer Med; 2021 Feb; 10(4):1253-1263. PubMed ID: 33455068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
    Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.